WO2005009439A1 - Muscarinic acetylcholine receptor antagonists - Google Patents
Muscarinic acetylcholine receptor antagonists Download PDFInfo
- Publication number
- WO2005009439A1 WO2005009439A1 PCT/US2004/022947 US2004022947W WO2005009439A1 WO 2005009439 A1 WO2005009439 A1 WO 2005009439A1 US 2004022947 W US2004022947 W US 2004022947W WO 2005009439 A1 WO2005009439 A1 WO 2005009439A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- azoniabicyclo
- dimethyl
- compound according
- carbon atoms
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- This invention relates to the olefinic derivatives of 8-azoniabicyclo[3.2.1] octanes, pharmaceutical compositions, and use thereof in treating muscarinic acetylcholine receptor mediated diseases of the respiratory tract.
- mAChRs Muscarinic acetylcholine receptors
- Muscarinic acetylcholine receptors are widely distributed in vertebrate organs where they mediate many of the vital functions. Muscarinic receptors can mediate both inhibitory and excitatory actions. For example, in smooth muscle found in the airways, M3 mAChRs mediate contractile responses. For review, please see Caulfield (1993 Pharmac. Ther. 58:319-79). In the lungs, mAChRs have been localized to smooth muscle in the trachea and bronchi, the submucosal glands, and the parasympathetic ganglia. Muscarinic receptor density is greatest in parasympathetic ganglia and then decreases in density from the submucosal glands to tracheal and then bronchial smooth muscle.
- Muscarinic receptors are nearly absent from the alveoli.
- mAChR expression and function in the lungs please see Fryer and Jacoby (1998 Am J Respir Crit Care Med 158(5, pt 3) S 154-60).
- M 3 mAChRs located on airway smooth muscle, mediate muscle contraction. Stimulation of M 3 mAChRs activates the enzyme phospholipase C via binding of the stimulatory G protein Gq/11 (Gs), leading to liberation of phosphatidyl inositol-4,5-bisphosphate, resulting in phosphorylation of contractile proteins.
- M 3 mAChRs are also found on pulmonary submucosal glands. Stimulation of this population of M 3 mAChRs results in mucus secretion. M mAChRs make up approximately 50-80% of the cholinergic receptor population on airway smooth muscles. Although the precise function is still unknown, they inhibit catecholaminergic relaxation of airway smooth muscle via inhibition of cAMP generation. Neuronal M mAChRs are located on postganglionic parasympathetic nerves. Under normal physiologic conditions, neuronal M mAChRs provide tight control of acetylcholine release from parasympathetic nerves. Inhibitory M 2 mAChRs have also been demonstrated on sympathetic nerves in the lungs of some species.
- Mj mAChRs are found in the pulmonary parasympathetic ganglia where they function to enhance neurotransmission. These receptors have also been localized to the peripheral lung parenchyma, however their function in the parenchyma is unknown. Muscarinic acetylcholine receptor dysfunction in the lungs has been noted in a variety of different pathophysiological states.
- COPD chronic bronchitis, chronic bronchiolitis and emphysema
- Smoking is the major risk factor for the development of COPD; nearly 50 million people in the U.S. alone smoke cigarettes, and an estimated 3,000 people take up the habit daily.
- COPD is expected to rank among the top five as a world-wide health burden by the year 2020.
- Inhaled anti-cholinergic therapy is currently considered the "gold standard" as first line therapy for COPD (Pauwels et al. 2001 Am. J. Respir. Crit. Care Med. 163:1256-1276).
- Combivent ⁇ in combination with albuterol is currently the only inhaled anti- cholinergic marketed for the treatment of airway hyperreactive diseases. While this compound is a potent anti -muscarinic agent, it is short acting, and thus must be administered as many as four times daily in order to provide relief for the COPD patient. In Europe and Asia, the long-acting anti-cholinergic Tiotropium Bromide
- topically active drugs that have long duration of action, and in particular, are retained either at the receptor or by the lung, would allow the avoidance of unwanted side effects that may be seen with systemic anti- cholinergic use.
- This invention provides for a method of treating a muscarinic acetylcholine receptor (mAChR) mediated disease, wherein acetylcholine binds to an mAChR and which method comprises administering an effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.
- This invention also relates to a method of inhibiting the binding of acetylcholine to its receptors in a mammal in need thereof which comprises administering to aforementioned mammal an effective amount of a compound of Formula (I).
- the present invention also provides for the novel compounds of Formula (I), and pharmaceutical compositions comprising a compound of Formula (I), and a pharmaceutical carrier or diluent.
- the compounds according to this invention have the structure shown by Formula (I):
- R2 and R3 are, independently, selected from the group consisting of straight or branched chain lower alkyl groups having preferably from 1 to 6 carbon atoms, cycloalkyl groups having from 5 to 6 carbon atoms, cycloalkyl-alkyl having 6 to 10 carbon atoms, 2-thienyl, 2-pyridyl, phenyl, phenyl substituted with an alkyl group having not in excess of 4 carbon atoms and phenyl substituted with an alkoxy group having not in excess of 4 carbon atoms.
- X " represents an anion associated with the positive charge of the N atom.
- X " may be but is not limited to chloride, bromide, iodide, sulfate, benzene sulfonate, and toluene sulfonate.
- Illustrative examples of this invention include (3-e «£/o)-3-(2,2-di-2-thienylethenyl)-8,8-dimethyl-8-azoniabicyclo[3.2.1]octane bromide;
- inhibitory effects of compounds at the M3 mAChR of the present invention are determined by the following in vitro and in vivo functional assays:
- Fluo-3- acetoxymethyl ester fluorescent indicator dye (Fluo-3 AM, Molecular Probes, Eugene, OR) and incubated 1 hr at 37° C. The dye-containing media was then aspirated, replaced with fresh media (without Fluo-3 AM), and cells were incubated for 10 minutes at 37° C.
- NMS in a SPA format is used to assess binding of muscarinic antagonists to Mi, M , M 3 , M 4 and M 5 muscarinic acetylcholine receptors.
- the SPA beads are pre-incubated with receptor-containing membrane for 30 min at 4°C. Then 50 mM HEPES and the test compound are added and incubated at room temperature (shaking) for 2 hours. The beads are then spun down and counted using a scintillation counter.
- the tissues were equilibrated under a resting tension of 1.5 g, determined to be optimal by length-tension evaluation, and washed with Krebs-Henseleit solution every 15 minutes for one hour. After the equilibration period pulmonary tissues were contracted with 10 uM carbachol until reaching plateau, which served as a reference contraction for data analysis. Tissues were then rinsed every 15 minutes over 1 hour until reaching baseline tone. The preparations were then left for at least 30 minutes before the start of the experiment. Concentration-response curves were obtained by a cumulative addition of carbachol in half-log increments (Van Rossum, 1963, Arch. Int. Pharmacodyn., 143:299), initiated at 1 nM.
- Muscarinic receptor antagonists infused at a single concentration per tissue until a sustained level of inhibition was attained. The compound was then removed and, once again, the carbachol-induced tension was allowed to recover. The following parameters were determined for each concentration of antagonist, and expressed as the mean ⁇ S.E.M. for n individual animals. Inhibition of the carbachol-induced contraction was expressed as a percent of the reference response (isoproterenol) and the time required to reach one-half of this relaxation was measured (onset of response). The tension recovery following removal of the compound was determined as was the time required to reach one-half of the maximum tension recovery (offset of response).
- Antagonist concentration-response curves were obtained by plotting the maximal relaxation data at 0, 60 and 180-min following antagonist withdrawal. Recovery, termed shift, was calculated from the ratio of the 0-min inhibition curve IC50 and the concentration of compound yielding a similar tension recovery at 60 and 180 minutes. Halftimes for onset and offset of response were plotted vs. corresponding concentration and the data were fit with non-linear regression.
- mice were allowed to equilibrate for 10 min before taking a baseline Penh measurement for 5 minutes. Mice were then challenged with an aerosol of methacholine (10 mg/ml) for 2 minutes. Penh was recorded continuously for 7 min starting at the inception of the methacholine aerosol, and continuing for 5 minutes afterward. Data for each mouse were analyzed and plotted by using GraphPad PRISM software. This experiment allows the determination of duration of activity of the administered compound.
- the present compounds are useful for treating a variety of indications, including but not limited to respiratory-tract disorders such as chronic obstructive lung disease, chronic bronchitis, asthma, chronic respiratory obstruction, pulmonary fibrosis, pulmonary emphysema, and allergic rhinitis.
- respiratory-tract disorders such as chronic obstructive lung disease, chronic bronchitis, asthma, chronic respiratory obstruction, pulmonary fibrosis, pulmonary emphysema, and allergic rhinitis.
- the present invention further provides a pharmaceutical formulation comprising a compound of formula (I), or a pharmaceutically acceptable salt, solvate, or physiologically functional derivative (e.g., salts and esters) thereof, and a pharmaceutically acceptable carrier or excipient, and optionally one or more other therapeutic ingredients.
- active ingredient means a compound of formula (I), or a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof.
- Compounds of formula (I) will be administered via inhalation via the mouth or nose.
- Dry powder compositions for topical delivery to the lung by inhalation may, for example, be presented in capsules and cartridges of for example gelatine, or blisters of for example laminated aluminium foil, for use in an inhaler or insufflator.
- Powder blend formulations generally contain a powder mix for inhalation of the compound of the invention and a suitable powder base (carrier/diluent/excipient substance) such as mono-, di- or poly-saccharides (e.g., lactose or starch), organic or inorganic salts (e.g., calcium chloride, calcium phosphate or sodium chloride), polyalcohols (e.g., mannitol), or mixtures thereof, alternatively with one or more additional materials, such additives included in the blend formulation to improve chemical and/or physical stability or performance of the formulation, as discussed below, or mixtures thereof.
- a suitable powder base such as mono-, di- or poly-saccharides (e.g., lactose or starch),
- Each capsule or cartridge may generally contain between 20 ⁇ g-10mg of the compound of formula (I) optionally in combination with another therapeutically active ingredient.
- the compound of the invention may be presented without excipients, or may be formed into particles comprising the compound, optionally other therapeutically active materials, and excipient materials, such as by co-precipitation or coating.
- the medicament dispenser is of a type selected from the group consisting of a reservoir dry powder inhaler (RDPI), a multi-dose dry powder inhaler (MDPI), and a metered dose inhaler (MDI).
- reservoir dry powder inhaler By reservoir dry powder inhaler (RDPI) it is meant as an inhaler having a reservoir form pack suitable for comprising multiple (un-metered doses) of medicament in dry powder form and including means for metering medicament dose from the reservoir to a delivery position.
- the metering means may for example comprise a metering cup or perforated plate, which is movable from a first position where the cup may be filled with medicament from the reservoir to a second position where the metered medicament dose is made available to the patient for inhalation.
- multi-dose dry powder inhaler MDPI
- the carrier has a blister pack form, but it could also, for example, comprise a capsule-based pack form or a carrier onto which medicament has been applied by any suitable process including printing, painting and vacuum occlusion.
- the formulation can be pre-metered (eg as in Diskus, see GB 2242134 or Diskhaler, see GB 2178965, 2129691 and 2169265) or metered in use (eg as in Turbuhaler, see EP 69715).
- An example of a unit-dose device is Rotahaler (see GB 2064336).
- the Diskus inhalation device comprises an elongate strip formed from a base sheet having a plurality of recesses spaced along its length and a lid sheet hermetically but peelably sealed thereto to define a plurality of containers, each container having therein an inhalable formulation containing a compound of formula (I) preferably combined with lactose.
- the strip is sufficiently flexible to be wound into a roll.
- the lid sheet and base sheet will preferably have leading end portions which are not sealed to one another and at least one of the said leading end portions is constructed to be attached to a winding means. Also, preferably the hermetic seal between the base and lid sheets extends over their whole width.
- the lid sheet may preferably be peeled from the base sheet in a longitudinal direction from a first end of the said base sheet.
- the multi-dose pack is a blister pack comprising multiple blisters for containment of medicament in dry powder form.
- the blisters are typically arranged in regular fashion for ease of release of medicament therefrom.
- the multi-dose blister pack comprises plural blisters arranged in generally circular fashion on a disk-form blister pack.
- the multi- dose blister pack is elongate in form, for example comprising a strip or a tape.
- the multi-dose blister pack is defined between two members peelably secured to one another. US Patents Nos. 5,860,419, 5,873,360 and 5,590,645 describe medicament packs of this general type.
- the device is usually provided with an opening station comprising peeling means for peeling the members apart to access each medicament dose.
- the device is adapted for use where the peelable members are elongate sheets which define a plurality of medicament containers spaced along the length thereof, the device being provided with indexing means for indexing each container in turn. More preferably, the device is adapted for use where one of the sheets is a base sheet having a plurality of pockets therein, and the other of the sheets is a lid sheet, each pocket and the adjacent part of the lid sheet defining a respective one of the containers, the device comprising driving means for pulling the lid sheet and base sheet apart at the opening station.
- metered dose inhaler it is meant a medicament dispenser suitable for dispensing medicament in aerosol form, wherein the medicament is comprised in an aerosol container suitable for containing a propellant-based aerosol medicament formulation.
- the aerosol container is typically provided with a metering valve, for example a slide valve, for release of the aerosol form medicament formulation to the patient.
- the aerosol container is generally designed to deliver a predetermined dose of medicament upon each actuation by means of the valve, which can be opened either by depressing the valve while the container is held stationary or by depressing the container while the valve is held stationary.
- Spray compositions for topical delivery to the lung by inhalation may for example be formulated as aqueous solutions or suspensions or as aerosols delivered from pressurised packs, such as a metered dose inhaler, with the use of a suitable liquefied propellant.
- Aerosol compositions suitable for inhalation can be either a suspension or a solution and generally contain the compound of formula (I) optionally in combination with another therapeutically active ingredient and a suitable propellant such as a fluorocarbon or hydrogen-containing chlorofluorocarbon or mixtures thereof, particularly hydrofluoroalkanes, e.g.
- the aerosol composition may be excipient free or may optionally contain additional formulation excipients well known in the art such as surfactants eg oleic acid or lecithin and cosol vents eg ethanol.
- Pressurised formulations will generally be retained in a canister (eg an aluminium canister) closed with a valve (eg a metering valve) and fitted into an actuator provided with a mouthpiece.
- Medicaments for administration by inhalation desirably have a controlled particle size.
- the optimum aerodynamic particle size for inhalation into the bronchial system for localized delivery to the lung is usually 1-1 O ⁇ m, preferably 2- 5 ⁇ m.
- the optimum aerodynamic particle size for inhalation into the alveolar region for achieving systemic delivery to the lung is approximately .5-3 ⁇ m, preferably 1-3 ⁇ m.
- Particles having an aerodynamic size above 20 ⁇ m are generally too large when inhaled to reach the small airways.
- Average aerodynamic particle size of a formulation may measured by, for example cascade impaction. Average geometric particle size may be measured, for example by laser diffraction, optical means. To achieve a desired particle size, the particles of the active ingredient as produced may be size reduced by conventional means eg by controlled crystallization, micronisation or nanomilling .The desired fraction may be separated out by air classification. Alternatively, particles of the desired size may be directly produced, for example by spray drying, controlling the spray drying parameters to generate particles of the desired size range. Preferably, the particles will be crystalline, although amorphous material may also be employed where desirable.
- the particle size of the excipient will be much greater than the inhaled medicament within the present invention, such that the "coarse" carrier is non-respirable.
- the excipient is lactose it will typically be present as milled lactose, wherein not more than 85% of lactose particles will have a MMD of 60-90 ⁇ m and not less than 15% will have a MMD of less than 15 ⁇ m.
- Additive materials' in a dry powder blend in addition to the carrier may be either respirable, i.e., aerodynamically less than 10 microns, or non-respirable, i.e., aerodynamically greater than 10 microns.
- Suitable additive materials which may be employed include amino acids, such as leucine; water soluble or water insoluble, natural or synthetic surfactants, such as lecithin (e.g., soya lecithin) and solid state fatty acids (e.g., lauric, palmitic, and stearic acids) and derivatives thereof (such as salts and esters); phosphatidylcholines; sugar esters.
- Additive materials may also include colorants, taste masking agents (e.g., saccharine), anti-static-agents, lubricants (see, for example, Published PCT Patent Appl. No.
- WO 87/905213 the teachings of which are inco ⁇ orated by reference herein
- chemical stabilizers e.g., stearic acid or polymers, e.g. polyvinyl pyrolidone, polylactic acid
- abso ⁇ tion enhancers e.g., abso ⁇ tion enhancers, and other materials known to those of ordinary skill.
- Sustained release coating materials e.g., stearic acid or polymers, e.g. polyvinyl pyrolidone, polylactic acid
- active material or active material containing particles see, for example, Patent Nos. US 3,634,582, GB 1,230,087, GB 1,381,872, the teachings of which are inco ⁇ orated by reference herein).
- Intranasal sprays may be formulated with aqueous or non-aqueous vehicles with the addition of agents such as thickening agents, buffer salts or acid or alkali to adjust the pH, isotonicity adjusting agents or anti-oxidants.
- Solutions for inhalation by nebulation may be formulated with an aqueous vehicle with the addition of agents such as acid or alkali, buffer salts, isotonicity adjusting agents or antimicrobials. They may be sterilised by filtration or heating in an autoclave, or presented as a non-sterile product.
- Preferred unit dosage formulations are those containing an effective dose, as herein before recited, or an appropriate fraction thereof, of the active ingredient.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Otolaryngology (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Priority Applications (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2004259232A AU2004259232A1 (en) | 2003-07-17 | 2004-07-16 | Muscarinic acetylcholine receptor antagonists |
EP04778451A EP1648460A4 (en) | 2003-07-17 | 2004-07-16 | Muscarinic acetylcholine receptor antagonists |
CA002532375A CA2532375A1 (en) | 2003-07-17 | 2004-07-16 | Muscarinic acetylcholine receptor antagonists |
BRPI0412716-1A BRPI0412716A (en) | 2003-07-17 | 2004-07-16 | muscarinic acetylcholine receptor antagonists |
JP2006520377A JP2007523877A (en) | 2003-07-17 | 2004-07-16 | Muscarinic acetylcholine receptor antagonist |
US10/565,046 US20060178395A1 (en) | 2003-07-17 | 2004-07-16 | Muscarinic acetylcholine receptor antagonists |
MXPA06000662A MXPA06000662A (en) | 2003-07-17 | 2004-07-16 | Muscarinic acetylcholine receptor antagonists. |
EA200600267A EA200600267A1 (en) | 2003-07-17 | 2004-07-16 | MUSCARINE RECEPTORS OF ACETYL CHOLINE ANTAGONISTS |
AP2006003478A AP2006003478A0 (en) | 2003-07-17 | 2004-07-16 | Muscarinic acetylcholine receptor antagonists. |
IL172822A IL172822A0 (en) | 2003-07-17 | 2005-12-26 | Muscarnic acetylcholine receptor antagonists |
EC2005006254A ECSP056254A (en) | 2003-07-17 | 2005-12-27 | ACETILCOLINE MUSCARINIC RECEPTORS ANTAGONISTS |
IS8302A IS8302A (en) | 2003-07-17 | 2006-02-14 | Múskarínasetýlkólínviðtakamótlyf |
NO20060775A NO20060775L (en) | 2003-07-17 | 2006-02-17 | Muscarine acetylcholine receptor antagonists |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US48798103P | 2003-07-17 | 2003-07-17 | |
US60/487,981 | 2003-07-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005009439A1 true WO2005009439A1 (en) | 2005-02-03 |
Family
ID=34102735
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2004/022947 WO2005009439A1 (en) | 2003-07-17 | 2004-07-16 | Muscarinic acetylcholine receptor antagonists |
Country Status (21)
Country | Link |
---|---|
US (1) | US20060178395A1 (en) |
EP (1) | EP1648460A4 (en) |
JP (1) | JP2007523877A (en) |
KR (1) | KR20060063890A (en) |
CN (1) | CN1822838A (en) |
AP (1) | AP2006003478A0 (en) |
AR (1) | AR045913A1 (en) |
AU (1) | AU2004259232A1 (en) |
BR (1) | BRPI0412716A (en) |
CA (1) | CA2532375A1 (en) |
EA (1) | EA200600267A1 (en) |
EC (1) | ECSP056254A (en) |
IL (1) | IL172822A0 (en) |
IS (1) | IS8302A (en) |
MA (1) | MA27900A1 (en) |
MX (1) | MXPA06000662A (en) |
NO (1) | NO20060775L (en) |
PE (1) | PE20050327A1 (en) |
TW (1) | TW200523261A (en) |
UY (1) | UY28417A1 (en) |
WO (1) | WO2005009439A1 (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1937230A2 (en) * | 2005-08-02 | 2008-07-02 | Glaxo Group Limited | M3 muscarinic acetylcholine receptor antagonists |
WO2010094643A1 (en) | 2009-02-17 | 2010-08-26 | Glaxo Group Limited | Quinoline derivatives and their uses for rhinitis and urticaria |
US8067408B2 (en) | 2008-02-06 | 2011-11-29 | Glaxo Group Limited | Dual pharmacophores—PDE4-muscarinic antagonistics |
US8071588B2 (en) | 2008-02-06 | 2011-12-06 | Glaxo Group Limited | Dual pharmacophores—PDE4-muscarinic antagonistics |
US8084449B2 (en) | 2008-02-06 | 2011-12-27 | Glaxo Group Limited | Dual pharmacophores—PDE4-muscarinic antagonistics |
EP2627317A2 (en) * | 2010-10-15 | 2013-08-21 | Glaxo Group Limited | Aggregate nanoparticulate medicament formulations, manufacture and use thereof |
US9763965B2 (en) | 2012-04-13 | 2017-09-19 | Glaxosmithkline Intellectual Property Development Limited | Aggregate particles |
WO2021191875A1 (en) | 2020-03-26 | 2021-09-30 | Glaxosmithkline Intellectual Property Development Limited | Cathepsin inhibitors for preventing or treating viral infections |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200519108A (en) * | 2003-07-17 | 2005-06-16 | Glaxo Group Ltd | Muscarinic acetylcholine receptor antagonists |
EA013689B1 (en) | 2003-10-14 | 2010-06-30 | Глэксо Груп Лимитед | Muscarinic acetycholine receptor antagonists |
MXPA06004242A (en) * | 2003-10-17 | 2006-06-28 | Glaxo Group Ltd | Muscarinic acetylcholine receptor antagonists field of the invention. |
PE20050489A1 (en) * | 2003-11-04 | 2005-09-02 | Glaxo Group Ltd | ANTAGONISTS OF MUSCARINE ACETYLCHOLINE RECEPTORS |
JP2007528420A (en) * | 2004-03-11 | 2007-10-11 | グラクソ グループ リミテッド | Novel M3 muscarinic acetylcholine receptor antagonist |
US20070185148A1 (en) * | 2004-03-17 | 2007-08-09 | Glaxo Group Limited | M3 muscarinic acetylchoine receptor antagonists |
EP1725564A4 (en) * | 2004-03-17 | 2007-09-12 | Glaxo Group Ltd | M3 muscarinic acetylcholine receptor antagonists |
UY28871A1 (en) | 2004-04-27 | 2005-11-30 | Glaxo Group Ltd | ANTAGONISTS OF THE MUSCARINIC ACETILCOLINE RECEIVER |
US7598267B2 (en) * | 2004-05-13 | 2009-10-06 | Glaxo Group Limited | Muscarinic acetylcholine receptor antagonists |
EP1957075A4 (en) * | 2004-11-15 | 2009-11-18 | Glaxo Group Ltd | Novel m3 muscarinic acetylcholine receptor antagonists |
TWI268704B (en) * | 2005-06-28 | 2006-12-11 | Realtek Semiconductor Corp | Apparatus and method for detecting vertical blanking interval |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2800478A (en) * | 1955-07-01 | 1957-07-23 | Smith Kline French Lab | 3-substituted-8-alkylnortropanes and the acid and quaternary ammonium salts thereof |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2800481A (en) * | 1955-07-01 | 1957-07-23 | Smith Kline French Lab | Tertiary alcohol derivatives of 8-alkylnortropanes and the acid and quaternary ammonium salts thereof |
US2800482A (en) * | 1955-07-01 | 1957-07-23 | Smith Kline French Lab | Olefinic derivatives of 8-alkylnortropanes and the acid and quaternary ammonium salts thereof |
JP2001505576A (en) * | 1996-12-02 | 2001-04-24 | ジョージタウン ユニバーシティ | Tropane derivatives and methods for their synthesis |
US6248752B1 (en) * | 1998-02-27 | 2001-06-19 | Charles Duane Smith | Azabicyclooctane compositions and methods for enhancing chemotherapy |
US6262066B1 (en) * | 1998-07-27 | 2001-07-17 | Schering Corporation | High affinity ligands for nociceptin receptor ORL-1 |
DE60008866T2 (en) * | 1999-05-04 | 2005-01-27 | Neurosearch A/S | HETEROARYL DIAZABICYCLOALKENE, THEIR PREPARATION AND USE |
ES2165768B1 (en) * | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | NEW DERIVATIVES OF QUINUCLIDINE AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM. |
CA2415468A1 (en) * | 2000-07-11 | 2003-01-10 | Yoshio Ogino | Ester derivatives |
EP1438309A1 (en) * | 2001-10-17 | 2004-07-21 | Ucb, S.A. | Quinuclidine derivatives, processes for preparing them and their uses as m2 and/or m3 muscarinic receptor inhibitors |
ATE435855T1 (en) * | 2003-11-21 | 2009-07-15 | Theravance Inc | COMPOUNDS HAVING AGONISTIC ACTION ON THE BETA2-ADRENERGIC RECEPTOR AND THE MUSCARINIC RECEPTOR |
-
2004
- 2004-07-15 PE PE2004000673A patent/PE20050327A1/en not_active Application Discontinuation
- 2004-07-15 AR ARP040102498A patent/AR045913A1/en unknown
- 2004-07-15 UY UY28417A patent/UY28417A1/en not_active Application Discontinuation
- 2004-07-15 TW TW093121062A patent/TW200523261A/en unknown
- 2004-07-16 MX MXPA06000662A patent/MXPA06000662A/en unknown
- 2004-07-16 EA EA200600267A patent/EA200600267A1/en unknown
- 2004-07-16 CA CA002532375A patent/CA2532375A1/en not_active Abandoned
- 2004-07-16 AU AU2004259232A patent/AU2004259232A1/en not_active Abandoned
- 2004-07-16 CN CNA2004800206494A patent/CN1822838A/en active Pending
- 2004-07-16 JP JP2006520377A patent/JP2007523877A/en not_active Withdrawn
- 2004-07-16 US US10/565,046 patent/US20060178395A1/en not_active Abandoned
- 2004-07-16 BR BRPI0412716-1A patent/BRPI0412716A/en not_active IP Right Cessation
- 2004-07-16 EP EP04778451A patent/EP1648460A4/en not_active Withdrawn
- 2004-07-16 WO PCT/US2004/022947 patent/WO2005009439A1/en active Application Filing
- 2004-07-16 AP AP2006003478A patent/AP2006003478A0/en unknown
- 2004-07-16 KR KR1020067001000A patent/KR20060063890A/en not_active Application Discontinuation
-
2005
- 2005-12-26 IL IL172822A patent/IL172822A0/en unknown
- 2005-12-27 EC EC2005006254A patent/ECSP056254A/en unknown
-
2006
- 2006-01-06 MA MA28704A patent/MA27900A1/en unknown
- 2006-02-14 IS IS8302A patent/IS8302A/en unknown
- 2006-02-17 NO NO20060775A patent/NO20060775L/en not_active Application Discontinuation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2800478A (en) * | 1955-07-01 | 1957-07-23 | Smith Kline French Lab | 3-substituted-8-alkylnortropanes and the acid and quaternary ammonium salts thereof |
Non-Patent Citations (1)
Title |
---|
DATABASE CAOLD [online] ZIRKLE ET AL.: "3-Substituted tropane derivatives-(III) 3-substituted tropane carbinol, alkenes and alkanes", XP002984395, accession no. STN Database accession no. CA58:4510b * |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1937230A2 (en) * | 2005-08-02 | 2008-07-02 | Glaxo Group Limited | M3 muscarinic acetylcholine receptor antagonists |
EP1937230A4 (en) * | 2005-08-02 | 2009-08-26 | Glaxo Group Ltd | M3 muscarinic acetylcholine receptor antagonists |
US8067408B2 (en) | 2008-02-06 | 2011-11-29 | Glaxo Group Limited | Dual pharmacophores—PDE4-muscarinic antagonistics |
US8071588B2 (en) | 2008-02-06 | 2011-12-06 | Glaxo Group Limited | Dual pharmacophores—PDE4-muscarinic antagonistics |
US8084449B2 (en) | 2008-02-06 | 2011-12-27 | Glaxo Group Limited | Dual pharmacophores—PDE4-muscarinic antagonistics |
WO2010094643A1 (en) | 2009-02-17 | 2010-08-26 | Glaxo Group Limited | Quinoline derivatives and their uses for rhinitis and urticaria |
EP2627317A2 (en) * | 2010-10-15 | 2013-08-21 | Glaxo Group Limited | Aggregate nanoparticulate medicament formulations, manufacture and use thereof |
EP2627317A4 (en) * | 2010-10-15 | 2014-08-20 | Glaxo Group Ltd | Aggregate nanoparticulate medicament formulations, manufacture and use thereof |
US9763965B2 (en) | 2012-04-13 | 2017-09-19 | Glaxosmithkline Intellectual Property Development Limited | Aggregate particles |
WO2021191875A1 (en) | 2020-03-26 | 2021-09-30 | Glaxosmithkline Intellectual Property Development Limited | Cathepsin inhibitors for preventing or treating viral infections |
Also Published As
Publication number | Publication date |
---|---|
AR045913A1 (en) | 2005-11-16 |
UY28417A1 (en) | 2005-02-28 |
MA27900A1 (en) | 2006-05-02 |
ECSP056254A (en) | 2006-04-19 |
NO20060775L (en) | 2006-04-11 |
MXPA06000662A (en) | 2006-03-30 |
EA200600267A1 (en) | 2006-06-30 |
EP1648460A1 (en) | 2006-04-26 |
AU2004259232A1 (en) | 2005-02-03 |
TW200523261A (en) | 2005-07-16 |
EP1648460A4 (en) | 2009-04-01 |
JP2007523877A (en) | 2007-08-23 |
IS8302A (en) | 2006-02-14 |
CA2532375A1 (en) | 2005-02-03 |
BRPI0412716A (en) | 2006-09-26 |
US20060178395A1 (en) | 2006-08-10 |
CN1822838A (en) | 2006-08-23 |
IL172822A0 (en) | 2006-06-11 |
PE20050327A1 (en) | 2005-06-08 |
AP2006003478A0 (en) | 2006-02-28 |
KR20060063890A (en) | 2006-06-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200600167B (en) | Muscarinic acetylcholine receptor antagonists | |
EP1682142B1 (en) | M3 muscarinic acetylcholine receptor antagonists | |
WO2006062931A2 (en) | Medical combinations | |
EP1740177B1 (en) | Muscarinic acetylcholine receptor antagonists | |
US7579345B2 (en) | Muscarinic acetylcholine receptor antagonists | |
US20060178395A1 (en) | Muscarinic acetylcholine receptor antagonists | |
US20060160844A1 (en) | Muscarinic acetylcholine receptor antagonists | |
WO2006062883A2 (en) | Medical combinations | |
EP1937068A2 (en) | Muscarinic acetylcholine receptor antagonists | |
US20070293531A1 (en) | Muscarinic Acetycholine Receptor Antagonists | |
US20090076061A1 (en) | Muscarinic acetycholine receptor antagonists |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200480020649.4 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 172822 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004259232 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12006500020 Country of ref document: PH |
|
WWE | Wipo information: entry into national phase |
Ref document number: 06000505 Country of ref document: CO Ref document number: 74/DELNP/2006 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: AP/P/2006/003478 Country of ref document: AP Ref document number: 200600168 Country of ref document: ZA |
|
ENP | Entry into the national phase |
Ref document number: 2532375 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 544694 Country of ref document: NZ Ref document number: 1020067001000 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: 2006178395 Country of ref document: US Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006520377 Country of ref document: JP Ref document number: 10565046 Country of ref document: US Ref document number: PA/a/2006/000662 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 2004259232 Country of ref document: AU Date of ref document: 20040716 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2004259232 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004778451 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: DZP2006000068 Country of ref document: DZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1200600230 Country of ref document: VN Ref document number: 200600267 Country of ref document: EA |
|
WWP | Wipo information: published in national office |
Ref document number: 2004778451 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020067001000 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 10565046 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: PI0412716 Country of ref document: BR |